Sanofi (NYSE:SNY) Given Daily News Sentiment Rating of 0.15
Media headlines about Sanofi (NYSE:SNY) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sanofi earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.9256987419341 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Regeneron to terminate antibody discovery partnership with Sanofi at year-end – Seeking Alpha (seekingalpha.com)
- The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise – Investor’s Business Daily (investors.com)
- Sanofi Q2/2017: Mixed Signals – Seeking Alpha (seekingalpha.com)
- Q3 2017 EPS Estimates for Sanofi Decreased by Leerink Swann (SNY) (americanbankingnews.com)
- Sanofi American Depositary Shar (SNY) Ownership Decreased by St. James Investment Company, LLC – Highlight Press (highlightpress.com)
SNY has been the subject of several recent analyst reports. J P Morgan Chase & Co upgraded shares of Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, April 11th. BidaskClub cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Friday, June 2nd. Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, HSBC Holdings plc cut shares of Sanofi from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $63.75.
Sanofi (NYSE SNY) traded up 0.84% on Friday, hitting $48.08. 1,172,670 shares of the stock traded hands. The stock has a market cap of $120.75 billion, a P/E ratio of 11.54 and a beta of 0.88. The stock has a 50-day moving average price of $48.11 and a 200 day moving average price of $45.82. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24.
Sanofi (NYSE:SNY) last announced its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities analysts expect that Sanofi will post $3.20 EPS for the current fiscal year.
WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/04/sanofi-nysesny-given-daily-news-sentiment-rating-of-0-15.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.